Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2022
2021
2020
Profitability Metrics
Gross Margin
40.67%
Operating Margin
130.67%
Net Margin
95.96%
Efficiency Metrics
Revenue per Expense Ratio
1.00
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
130.67%
Income Tax Rate
0.00%
EPS
0.9300000000
Balance Sheet Analysis
Current Ratio
0.00
Cash Ratio
0.00
Working Capital
$-119.16M
Debt to Equity
0.31
Debt to Assets
23.36%
Equity Ratio
74.99%
Cash Flow Analysis
Operating Cash Flow Ratio
117.50%
Free Cash Flow Ratio
117.50%
CapEx to Revenue
0.00%
Dividends Paid
$34.18M
Stock Buybacks
No buybacks
Total Shareholder Returns
$34.18M
Cash Position Change
-10.48%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Increased dividend payments by 4.26%
Increased R&D investment by 100.00%
Detailed Growth Metrics
Core Performance
Revenue
230.86%
Net Income
217.51%
EPS
216.25%
Operating Income
260.01%
Operational Efficiency
R&D Expenses
100.00%
SG&A Expenses
-23.13%
Operating Cash Flow
-73.00%
Free Cash Flow
-73.00%
Balance Sheet Health
Assets
2.96%
Debt
-6.23%
Book Value per Share
2.87%
Inventory
-100.00%
Shareholder Returns
Dividends per Share
4.26%
Shares Outstanding
1.12%
Long Term Trends
3Y Revenue/Share
-52.71%
5Y Revenue/Share
-38.57%
3Y Dividend/Share
8.61%
5Y Dividend/Share
-1.93%